Table 1_The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy.docx

<p>Antibody-drug conjugates (ADCs) offer targeted cancer therapy by delivering cytotoxic agents directly to tumor cells. However, challenges such as relapse, resistance, and diverse patient needs drive ongoing innovation in ADC development. Exploration of new small-molecule toxins with unique...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Huihui Guo (116685) (author)
مؤلفون آخرون:	Hongsheng Xie (716868) (author), Yuanyuan Huang (671992) (author), Junxiang Jia (18203483) (author), Xiangfei Kong (1909192) (author), Qingliang Yang (493947) (author), Shun Gai (20697275) (author), Wenjun Li (41954) (author), Lu Bai (343118) (author), Lingli Zhang (160932) (author), Xiaoxiao Chen (1673935) (author), Zhicang Ye (1520740) (author), Hangbo Ye (18215725) (author), Linyao Zhao (11183196) (author), Yifang Xu (18215728) (author), Yong Du (86188) (author), Xiuzhen Zhang (2309947) (author), Miaomiao Chen (763128) (author), Xiaomai Zhou (20317484) (author), Robert Y. Zhao (2196925) (author)
منشور في:	2025
الموضوعات:	Pharmacology Tub114 DX126-262 tubulysin B analog target-specific delivery HER2 therapeutic window ADC
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

Table 1_The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy.docx

مواد مشابهة